Colorectal Cancer Articles

Phase III MABp1 Colorectal Cancer Study Discontinued
Following a second prospectively planned, unblinded analysis, drug manufacturer XBiotech has cancelled the phase III XCITE study of MABp1 (Hutruo; formerly Xilonix) in patients with advanced colorectal cancer.
Study Backs 50% Chemo Cutback After Surgery for Low-Risk Colon Cancer
Most patients with low-risk advanced colon cancer would benefit from a 50% reduction in the oxaliplatin-containing chemotherapy they typically receive after surgery without notably increasing their risk of recurrence and while markedly decreasing the likelihood that they will develop neuropathy, according to an analysis that challenges the current standard of care and paves the way for a more personalized approach.
FDA Approves Pembrolizumab for Microsatellite Instability-High and Mismatch Repair Deficient Cancers
The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
Adopting Healthy Lifestyle Leads to Improved Overall Survival in Postsurgical Colon Cancer
Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.
Eating Nuts After Colon Cancer Improves Survival and Lowers Recurrence Risk
Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.
Genomic Findings Reshaping CRC Field

Extensive studies into molecular aberrations in colorectal cancer are yielding fresh insights into the potential clinical utility of checkpoint immunotherapies, genetic testing, and tumor-sidedness implications. Experts weigh in on key developments that may change treatment paradigms. 

Fahima Dossa, MD, discussed the potential of using a watch-and-wait approach in the management of patients with rectal cancer.
Researchers Perform First Robotic Colonoscopy
Researchers have successfully performed autonomous retroflexion of a robotic capsule during colonoscopy in a subject animal, according to data presented during Digestive Disease Week 2017 at McCormick Place in Chicago.
Inherited Mutations Play Greater Role in CRC Than Previously Thought
Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.
Novel Drug Targets Cancer Stem Cell Pathway in Metastatic CRC Trial
The international CanStem303C trial is evaluating the combination of napabucasin, the most advanced cancer stemness inhibitor in development, with FOLFIRI chemotherapy in patients with previously treated metastatic colorectal cancer.
Publication Bottom Border
Border Publication